American Society of Hirudotherapy

Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients

Review published in American heart journal (2011)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Narrative reviewClinical LiteratureSafety & Infection ControlSellers MB et al. · American heart journal, 2011

Abstract

Atrial fibrillation (AF) affects 2.5 million patients in the United States. The incidence of this condition increases with age, such that approximately 5% of people > 65 years of age have AF. Because of the lack of organized atrial contraction and thrombus formation in the left atrium, patients with AF are at increased risk of stroke. The estimated risk of stroke among all AF patients is 5% per year. Among patients without mitral stenosis, there is a graded relationship of stroke risk with the number of CHADS₂ risk factors. Warfarin is the recommended treatment for embolic stroke prophylaxis in AF in intermediate- to high-risk patients. However, elderly patients who are deemed to be at risk of falls are often not started on warfarin therapy secondary to a perceived higher risk of bleeding complications. These risks have been evaluated, but conclusive data regarding the risk-benefit trade-off are elusive. This review summarizes available data on the use of warfarin in elderly patients with AF, focusing on the risk of bleeding, and will specifically address the utility of falls risk assessment in the decision to initiate warfarin therapy for AF.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAccidental FallsAgedAnticoagulantsAtrial FibrillationForecastingHemorrhageHumansRisk FactorsTreatment OutcomeWarfarin

Summary

This review summarizes data on warfarin use for stroke prevention in elderly patients with atrial fibrillation, addressing bleeding risk and whether falls-risk assessment should influence the decision to start anticoagulation, noting that conclusive risk-benefit data remain elusive.

Context

This narrative review summarizes the use of warfarin for stroke prophylaxis in elderly atrial-fibrillation patients, noting that AF raises stroke risk in a graded relationship with CHADS2 risk factors and that older patients judged to be at fall risk are frequently denied warfarin out of bleeding concern, while acknowledging that conclusive risk-benefit data on the falls question remain elusive. This is a 2011 review of warfarin-era evidence with no randomized data of its own, predates routine direct-oral-anticoagulant use, and has no connection to leech therapy.

Citation

Reference (Vancouver style)

Sellers MB, Newby LK. Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients. Am Heart J. 2011;161(2):241-246. doi:10.1016/j.ahj.2010.11.002. PMID: 21315204

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.